Showing posts with label blood. Show all posts
Showing posts with label blood. Show all posts

Sunday, April 20, 2008

Extra Pounds During and Between Pregnancies Can Pose Problems

(HealthDay News) -- Pregnancy has long been considered a kind of gastronomical free-for-all. After all, a pregnant woman has to nourish two bodies with the food she eats, right?

The problem is, the baby's nutritional needs are only around 300 calories a day, and extra weight gain can increase the risk of pregnancy complications for both mother and child.

And, weight concerns don't stop after the baby is born, because extra weight gain after pregnancy increases the risk of complications in subsequent pregnancies, even if a woman never gains enough to be considered overweight.

"Women think they have carte blanche to eat whatever they want during pregnancy, but that's not a good idea," said Dr. Miriam Greene, a clinical assistant professor of obstetrics and gynecology at New York University Medical Center and the author of the book, Frankly Pregnant: A Candid, Week-by-Week Guide to the Unexpected Joys, Raging Hormones, and Common Experiences of Pregnancy.

"If you eat for two, you'll end up with complications you didn't need to take on. Eat what your appetite tells you to eat, and eat slowly, so you can tell when you're full," advised Dr. Marjorie Greenfield, an obstetrician at MacDonald Women's Hospital at Case Medical Center, University Hospitals in Cleveland, and author of the book, The Working Woman's Pregnancy Book.

During pregnancy, an average-weight woman should gain about 25 to 35 pounds, according to Greene. "You don't want your weight gain to be less than 15 or greater than 40," she said.

But many women aren't heeding that advice. A recent report from the Institute of Medicine (IOM) found that about one-quarter of American women gain more than 40 pounds during their pregnancy. The IOM is currently reviewing its guidelines on pregnancy weight gain and expects to issue new guidelines during the summer of 2009.

In the meantime, the IOM recommends that women with a body mass index (BMI, a ratio of weight to height) of less than 18.5 should gain 28 to 40 pounds during pregnancy, while women with an average BMI -- 18.5 to 24.9 -- should keep weight gain between 25 and 35 pounds. Overweight women with BMIs of 25 to 29.9 should try to gain between 15 and 25 pounds throughout their pregnancy, and obese women with BMIs over 30 need only gain 15 pounds.

Gaining too much weight during pregnancy puts both baby and mom at risk of complications, such as gestational diabetes and high blood pressure, labor complications, stillbirth and delivery of a large-for-gestational age baby, according to the March of Dimes.

Greene said about two-thirds of her patients manage to stay within the guidelines. And those who don't are very disappointed at how hard the weight is to get off afterward.

She recommends that her pregnant patients eat well-balanced diets and that they don't give in to every food craving. "It's not healthy to gain weight eating pints of ice cream," she said.

Greenfield is also a fan of most exercises during pregnancy. Not only can exercise help you stave off pregnancy weight gain, it improves overall well-being as well, she said.

"Pregnancy is a special time when a lot of women will take better care of themselves to take care of the baby. It's a golden opportunity to take care of yourself, and you may have an impact on your health and your baby's health in the long run," Greenfield noted.

And, it's not just during pregnancy that women have to be concerned about extra pounds. A recent study found that every one or two point increase in a woman's BMI between pregnancies translated to an increased risk of gestational diabetes, high blood pressure and delivering a large baby by 20 percent to 40 percent. Women who increased their BMI more than three points between pregnancies had a 63 percent increased risk of delivering a stillborn baby.

The increases in the risks of complications held true even if the BMI changes didn't place a woman into the overweight or obese category, the study found.




More information
To learn more about weight gain during pregnancy, visit the American Pregnancy Association.

Friday, April 11, 2008

Meaning and Principles of Ayurveda

Ayurveda comprising of Ayur (life) and Veda (Scince or knowledge) is a holistic healing science which is in other words called “Science of life”.

Ayurveda deals with the complete way of life, rather than just the treatment of diseases.Basic principlesAyurveda considers the humanity and universe as a common origin, and considers nature to […]

Monday, March 10, 2008

Kama Yogi

Kama Yogi's benefits include:

Harmony of the body, mind, and spirit
Stronger not allowed drive
Bigger, harder, and more frequent erections
Greater sexual pleasure and more intense orgasms
Greater confidence and mastery of not allowed life
Greater strength, flexibility, and balance
Reduced stress and anxiety
Slower heart rate
Lower blood pressure
Improved circulation
Detoxification of bodily systems
Improved functioning of internal organs
Increased metabolism and energy

more information:

Tuesday, January 29, 2008

Caffeine Could Spell Trouble for Diabetics

(HealthDay News) -- New research suggests the caffeine in those daily cups of java might spell blood sugar trouble for diabetics.

In a small group of 10 diabetics, glucose levels rose by 8 percent when participants took pills filled with the level of caffeine found in four cups of coffee.

"There's reason to believe that caffeine consumption -- and coffee is the most common source of caffeine -- may be harmful to people with type 2 diabetes and make it more difficult for them to keep their glucose levels under proper control," said study author James Lane, a professor of medical psychology at Duke University.

While some research has suggested that the antioxidants in coffee could prevent diabetes in women, laboratory tests have questioned whether caffeine disrupts the body's ability to process blood sugar. "We want to demonstrate that what we've seen in the lab takes place in the real world when people are living their normal lives," Lane said.

In the new study, researchers inserted a small sensor into the abdomens of 10 patients who had diabetes but didn't take insulin. The sensor kept track of blood sugar levels for up to 72 hours.

Over several days, the patients -- all coffee drinkers -- alternated between taking placebos and 500 milligrams of caffeine a day in capsule form. That level of caffeine is equal to four eight-ounce cups of coffee.

The findings appear in the February issue of Diabetes Care.

On days when they consumed the caffeine pills, the blood sugar levels of the patients went up by 8 percent compared to when they took placebos. Glucose also rose after meals, most notably after dinner when blood sugar levels grew by 26 percent.

There are a couple possible explanations, according to Lane. In one, caffeine may interfere with the transfer of glucose from blood into the cells of the body, boosting blood sugar levels. Another possibility, he said, is that caffeine may stimulate the liver to release glucose when it's not needed.

A researcher who studies coffee said the new study has some limitations. For one, it looks at effects over one day, rather than over the long term, said Rob van Dam, a research scientist at Harvard School of Public Health. For another, "it should be noted that effects of caffeine in capsules cannot be directly translated to effects of caffeinated coffee, as studies have previously found less pronounced effects of caffeinated coffee on blood glucose levels as compared with caffeine in isolation," he added.

What to do? Keep coffee consumption under control, Lane suggested. "It would be worthwhile for people with diabetes who drink coffee to try quitting for a time and see if their glucose improves," Lane said. "It's a simple thing that might make their diabetes better."

Decaf may also do the trick. Indeed, van Dam said a previous study showed decaffeinated coffee actually reduced spikes in glucose levels after people ate sugary food. "It may thus be useful for persons with diabetes to try switching from caffeinated to decaffeinated coffee and see whether this improves their glycemic control, he said.

More information
Learn more about diabetes from the National Institutes of Health.

Caffeine Could Spell Trouble for Diabetics

(HealthDay News) -- New research suggests the caffeine in those daily cups of java might spell blood sugar trouble for diabetics.

In a small group of 10 diabetics, glucose levels rose by 8 percent when participants took pills filled with the level of caffeine found in four cups of coffee.

"There's reason to believe that caffeine consumption -- and coffee is the most common source of caffeine -- may be harmful to people with type 2 diabetes and make it more difficult for them to keep their glucose levels under proper control," said study author James Lane, a professor of medical psychology at Duke University.

While some research has suggested that the antioxidants in coffee could prevent diabetes in women, laboratory tests have questioned whether caffeine disrupts the body's ability to process blood sugar. "We want to demonstrate that what we've seen in the lab takes place in the real world when people are living their normal lives," Lane said.

In the new study, researchers inserted a small sensor into the abdomens of 10 patients who had diabetes but didn't take insulin. The sensor kept track of blood sugar levels for up to 72 hours.

Over several days, the patients -- all coffee drinkers -- alternated between taking placebos and 500 milligrams of caffeine a day in capsule form. That level of caffeine is equal to four eight-ounce cups of coffee.

The findings appear in the February issue of Diabetes Care.

On days when they consumed the caffeine pills, the blood sugar levels of the patients went up by 8 percent compared to when they took placebos. Glucose also rose after meals, most notably after dinner when blood sugar levels grew by 26 percent.

There are a couple possible explanations, according to Lane. In one, caffeine may interfere with the transfer of glucose from blood into the cells of the body, boosting blood sugar levels. Another possibility, he said, is that caffeine may stimulate the liver to release glucose when it's not needed.

A researcher who studies coffee said the new study has some limitations. For one, it looks at effects over one day, rather than over the long term, said Rob van Dam, a research scientist at Harvard School of Public Health. For another, "it should be noted that effects of caffeine in capsules cannot be directly translated to effects of caffeinated coffee, as studies have previously found less pronounced effects of caffeinated coffee on blood glucose levels as compared with caffeine in isolation," he added.

What to do? Keep coffee consumption under control, Lane suggested. "It would be worthwhile for people with diabetes who drink coffee to try quitting for a time and see if their glucose improves," Lane said. "It's a simple thing that might make their diabetes better."

Decaf may also do the trick. Indeed, van Dam said a previous study showed decaffeinated coffee actually reduced spikes in glucose levels after people ate sugary food. "It may thus be useful for persons with diabetes to try switching from caffeinated to decaffeinated coffee and see whether this improves their glycemic control, he said.

More information
Learn more about diabetes from the National Institutes of Health.Last reviewed: 01/28/2008 Last updated: 01/28/2008

Wednesday, December 26, 2007

Health Tip: Get Plenty of Potassium

(HealthDay News) - Potassium is a dietary mineral that's vital to the body and healthy cell function. A big drop in the body's potassium levels can be life-threatening, the U.S. National Library of Medicine says.

The agency lists common symptoms of potassium deficiency:

  • An abnormal heart rhythm (particularly in people with heart conditions).
  • Constipation.
  • Fatigue.
  • Weakness in the muscles, or muscle spasms.
  • Paralysis, including paralysis of the lungs.


more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Wednesday, December 12, 2007

Kama Raja

In order for erection to occur, the nerves of the penis must be functioning properly, blood circulation to the penis must be adequate, and there must be stimulus from the brain. If there is something interfering with any or all of these conditions, a full erection is not possible.

Common causes for erectile dysfunction include diseases that affect blood flow and nerves, psychological factors such as stress, depression, and performance anxiety, and injury to the penis.

According to the National Institutes of Health, a majority of men at some point in their life experience occasional failure to achieve erection which can occur for a variety of reasons such as drinking too much alcohol or from being extremely tired.

Failure to achieve erection less than 20% of the time is not unusual and medical treatment is rarely needed. But the causes for this minor problem might lead to a permanent condition where failure to achieve erection occurs more than 50% of the time.

Once this stage of erectile dysfunction is reached, medical treatment is required to reverse the situation. Approximately 5 percent of 40-year-old men and between 15 and 25 percent of 65-year-old men experience erectile dysfunction on a long-term basis.

Western medicine relies on aggressive prescription drugs and surgery to deal with many problems related to sexual dysfunction. Unfortunately, these methods often result in unwanted and even dangerous side effects. Non-medical methods of penis enhancement through exercise using weights, straps, rings, and pumps have proven destructive to muscle tissue.

And natural pills provide fleeting, inconsistent results. Ayurveda, the science of life, prevention and longevity, is the oldest and most holistic and comprehensive medical system available. Its fundamentals can be found in Hindu scriptures called the Vedas - the ancient Indian books of wisdom written over 5,000 years ago. Ayurveda uses the inherent principles of nature to help maintain health in a person by keeping the individual's body, mind, and spirit in perfect equilibrium with nature.

India Herbs has a seasoned group of Ayurvedic doctors specialized in Vajikarana, one of the eight major specialties of Ayurveda. Vajikarana is "a process or a drug, which make a man sexually as strong as a horse and able to copulate for long and frequently with many wives and partners." Vajikarana prescribes the therapeutic use of various aphrodisiacs and tonic preparations for enhancing the reproductive capabilities and vigor of men while strengthening the body and overall well-being.

India Herbs' Vajikarana doctors combine a proprietary herbal formula based on centuries' old wisdom with advice on diet, exercise, mental training, and relaxation to help men reach their peak and overcome sexual concerns through safe, natural means. Results: The precise combination of ingredients in Kama Raja along with a mind-body focus precisely addresses the sexual concerns of men!

more information @ http://www.kamaraja.com/index.htm?aff=dreddyclinic


Sunday, December 02, 2007

Health Tip: The Road to a Healthy Heart

(HealthDay News) -- The American Heart Association says there are a few simple things you can do to keep active and promote a healthier heart:
  • Do housework yourself, instead of hiring someone else to do it.
  • Work in the garden or mow the grass. Using a riding mower doesn't count.
  • Go out for a short walk before breakfast, after dinner or both. Start with a 10-minute walk and work up to 30 minutes.
  • Walk or bike to the corner store.
  • When watching television, pedal a stationary bicycle.
  • Park on the outskirts of a shopping mall and walk to the stores.

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Friday, November 30, 2007

We Can! Program Takes Aim at Childhood Obesity

(HealthDay News) -- The U.S. National Institutes of Health and the Association of Children's Museums are teaming up on a program to combat the obesity epidemic among America's children.

The program -- called We Can! (Ways to Enhance Children's Activity and Nutrition) -- was introduced Thursday in Boston, Las Vegas and Pittsburgh, which have been designated as We Can! cities.

Other We Can! communities include Armstrong County, Pa.; Carson City, Nev.; Gary, Ind.; South Bend, Ind.; and Roswell, Ga.

"I am really confident that this partnership among the federal government, the We Can! program, the Association of Children's Museums and civic organizations is ultimately going to lead to healthier children in the United States, healthier families and better health-care outcomes for everybody," acting U.S. Surgeon General Rear Admiral Dr. Steven K. Galson said during an afternoon teleconference.

Dr. Elias Zerhouni, director of the National Institutes of Health, said childhood obesity has reached "crisis" proportions.

"We are facing a crisis, and we must find ways to change the tide that is facing us and affecting our children," Zerhouni said during the teleconference.

There are more than 12.5 million overweight children and teens in the United States. Galson said obesity is a big contributor to such childhood health problems as high cholesterol, type 2 diabetes and asthma.

"Chronic diseases cause seven out of 10 deaths," Galson said. "And the costs are staggering."

Galson noted that portion sizes have increased while life in America has become more sedentary. "Our kids are growing up with unhealthy lifestyles, the consequences of which could be with them for the rest of their lives," he said.

"Reversing this epidemic does not have one answer," he added. "It's going to take a concerted action by all of us. We need to focus our activities on prevention -- on what we can do today."

We Can! can be a model for overcoming the challenges of childhood obesity and overweight, Galson said. "Its partnerships are demonstrating how physical activity and sound lifestyle choices can make a difference and how communities can work together to make those lifestyle choices real," he said.

We Can! is an education program to help children aged 8 to 13 years old to maintain a healthy weight. It's being implemented in more than 450 communities in 44 states.

Zerhouni said getting kids away from the TV and the computer is key to improving their health. Increased activity, better food choices and smaller portions complete the arsenal for fighting the obesity epidemic, he said.

The three new We Can! cities announced Thursday are introducing the program to city employees, community groups, corporate wellness programs, health professionals and schools.

While improvement in childhood obesity is vital, the results may not be seen for decades, Galson said.

"It's a national necessity with profound implications -- we all have a stake in the outcome," he said. "The result may not be apparent for many years, but it's going to be a fitter, healthier, more physically active nation in which the epidemic of childhood obesity slows down."

In addition to the Association of Children's Museums, 40 national and corporate partners are starting We Can! programs in community centers, schools, health-care settings, corporate wellness programs and faith-based organizations, officials said.

A study this week by the U.S. Centers for Disease Control and Prevention found that after increasing for the last 25 years, the prevalence of obesity among adults has not risen in the past few years. Still, 34 percent of Americans aged 20 and older are obese.

"In view of these alarmingly high rates of obesity in all population groups, [the] CDC has made the prevention of obesity one of its top public health priorities," Janet Collins, director of CDC's National Center for Chronic Disease Prevention and Health Promotion, said in a prepared statement. "We are actively working in partnership with state and local public health agencies, the nation's schools, community organizations, businesses, medical systems and faith communities to promote and support healthy eating, physical activity and healthy weight."

More information
To learn more about the We Can! program, visit the U.S. National Heart, Lung, and Blood Institute.

Thursday, October 11, 2007

Health Tip: Say Cheers With Red Wine

(HealthDay News) -- Red wine has been shown to help improve cardiovascular health, most likely because it is rich in antioxidants called flavonoids.

You should limit yourself to a 4-ounce glass of wine daily, Yale-New Haven Hospital advises. But check with your doctor, especially if you presently don't drink alcohol.

Here's more information:
  • Drinking for health should be done only in moderation -- binge drinking or drinking large amounts of alcohol is dangerous.
  • If you have health problems such as liver disease, very high blood pressure or depression, you should not drink alcohol.
  • Wines thought to contain the highest concentrations of flavonoids are Cabernet Sauvignon, Petit Syrah and Pinot Noir.

Saturday, September 29, 2007

Meditation May Help Rheumatoid Arthritis Sufferers

(HealthDay News) -- For rheumatoid arthritis sufferers whose painful illness prompts depression, relief may come from the practice of an age-old technique already embraced by millions around the world: meditation.

Researchers found that a half-year exposure to meditation techniques helped patients shave as much as one-third of their psychological distress.

The research team, led by Elizabeth K. Pradhan of the University of Maryland School of Medicine's Center for Integrative Medicine, based its conclusions on an analysis of a specific training course called "Mindfulness-Based Stress Reduction" (MBSR).

Pradhan and her colleagues said the MBSR concept of "mindfulness" is designed to guide patients to focus on the "here and now," while emphasizing the value of calmness, clarity, well-being, and a compassion for oneself and others.

The Arthritis Foundation has said that several so-called "mind-body practices" may help arthritis patients alleviate stress, pain, anxiety and depression.

In addition to meditation, the organization acknowledges the potential of electronic monitoring techniques such as biofeedback; the mental health benefits of guided imagery and hypnosis; and the ability of physical activities such as yoga and tai chi to both calm and energize patients.

The Maryland researchers noted that prior studies had already shown that the MBSR course, in particular, seems to have a positive impact on the psychological symptoms of patients with conditions such as anxiety disorders, chronic pain, fibromyalgia, cancer and multiple sclerosis.

Patients recovering from organ transplant surgery also seem to derive some benefit, the researchers said.

For their study, published in the October issue of Arthritis Care & Research, Pradhan and her colleagues focused specifically on rheumatoid arthritis. It was the first-ever analysis of MBSR and its impact on depression, general well-being, and disease progression among rheumatoid arthritis patients, the researchers said.

Thirty-one patients were offered the mediation course over an eight-week period, followed by a four-month maintenance program. Another 32 patients did not participate but were told they would be offered free meditation training once the study was completed.

With an average age of 54, most of the patients were female, white, married, college-educated, middle-class, and all were free of either psychiatric illness or alcohol or drug addiction.

During the trial, all the patients continued to be treated by their regular doctor and to take whatever medication they'd been taking before the study began.

At the start of the study, and two and six months later, all the patients completed questionnaires to assess depressive symptoms and psychological distress. Also, blood measures of inflammation were taken and an assessment of tender and swollen joints was done to evaluate current RA status.

By the two-month mark, both the meditation and the non-meditation groups had shown equal levels of improvement in terms of depression and emotional symptoms.

But by six months, there was a "significant" difference in perceived psychological distress between the two groups -- those practicing mediation reported a 35 percent reduction in psychological distress.

The researchers emphasized, however, that the meditation had no impact on the progression and activity of RA disease itself.

Pradhan and her team concluded that the meditation technique offered rheumatoid arthritis patients a safe and appealing way to improve their sense of well-being, when offered alongside traditional medical care.

"There's a fair amount of emotional distress that accompanies RA in terms of stability, worrying about the future, worrying about the ability to take care of oneself, to keep a job, to say nothing about the daily pain," Pradhan said. "There's just a lot to deal with. So, I think this is a novel and innovative way to handle this emotional distress and one that hasn't been tried before, and we were happy to see that it did make a difference along those lines.

"It doesn't really change disease status. That didn't happen," she said. "But in terms of ability to cope with a chronic and debilitating condition, meditation did appear to be quite helpful. And there was really high satisfaction with the intervention. So, I think this bodes well for the future.

"The other thing I think is important to note about our study," Pradhan said, "is that mindfulness meditation can be combined with any rheumatological therapy. It is truly complementary medicine in that sense, done in addition to pharmacological or other intervention. So, for physicians and patients who wonder what they can do to improve well-being, beyond taking medications, this study offers evidence for a beneficial approach to dealing with the psychological distress of RA.

Dr. Stephen Lindsey, head of rheumatology at Ochsner Health Systems in Baton Rouge, La., applauded Pradhan and her team for managing to get a scientific handle on a phenomenon he has observed throughout his practice.

"If someone is having stress and trouble with their arthritis, if you can somehow decrease the stress, you might be able to increase their function," Lindsey said. "And when you're meditating, you're trying to relax your body and get rid of the tension. It doesn't necessarily have to be a meditation scheme. It could be yoga, or Pilates, or a self-help course. But I'm in favor of using everything possible to help people, and this would be just one more way to help patients improve their lives."

More information
To learn more about meditation and arthritis, visit the Arthritis Foundation.

Tuesday, September 25, 2007

Health Tip: Controlling Foot Odor

(HealthDay News) - Sweaty feet and shoes that don't allow for circulation can lead to fungus and bacteria breeding inside your shoes and socks. These germs can cause an embarrassing odor when you remove your shoes.

Here are suggestions on how to reduce foot odor, courtesy of the American Academy of Orthopaedic Surgeons:
  • Wash feet thoroughly each day with soap and water, then dry thoroughly to prevent bacterial growth.
  • Change shoes and socks frequently -- at least once a day.
  • Apply daily a non-medicated powder, like baby powder or foot powder.
  • Check your feet for any signs of fungal or bacterial infection, and treat any symptoms promptly.
  • Wear thick, absorbent cotton socks with shoes.
  • Wear shoes made of breathable materials, like canvas, leather or mesh, and avoid plastic or nylon shoes.
  • Don't wear the same pair of shoes two days in a row.

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Thursday, September 20, 2007

Health Tip: Risk Factors for Gallstones

(HealthDay News) -- Gallstones are formed when bile inside the gallbladder hardens into rock-like pieces. They may or may not be painful, and may have to be removed or broken apart if they're causing problems such as infection.

Here are common risk factors for gallstones, courtesy of the U.S. National Digestive Diseases Information Clearinghouse:
  • Retaining excess estrogen, from pregnancy, birth control pills or hormone replacement therapy.
  • Having a family history of gallstones.
  • Being overweight or obese.
  • Undergoing excessive, rapid weight loss, which can be characteristic of fad dieting.
  • Eating a diet low in fiber and high in cholesterol and fat.
  • Having diabetes.

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Monday, September 17, 2007

Genetics Hold Promise, Challenges for Cancer Care

(HealthDay News) -- Someday in the future, people may routinely have doctors scan their personal genomes, looking for this or that aberrant gene to help prevent, spot or treat a cancer.

"We are in the midst of both an evolution and a revolution in cancer care," said Dr. Len Lichtenfeld, deputy chief medical officer at the American Cancer Society.

While gene-specific treatments such as the leukemia "wonder drug" Gleevec are already on the scene, "we still have an incredibly long way to go in terms of how we understand the basic genetics of cancer," he said.

"Right now, we are working still at a very crude level -- the future will be much more dynamic," Lichtenfeld said.

The "genetics generation" has much to be proud of, however. The mapping of the human genome in the late 1990s, the advent of high-output methods to comb through thousands of genes, and a deepening knowledge of the complexities of DNA and RNA are bringing new discoveries each week.

Some of the highlights from just the past year:

Last August, a U.S. team announced the first-ever gene test aimed at pinpointing which patients with early stage lung cancer will benefit from post-operative chemotherapy, and which can be spared the arduous treatment.

That same month, Canadian researchers reported on a new model to speed the identification of mutations linked to a silent killer, ovarian cancer. Spotting those genes could pinpoint women at risk.

A $100 million U.S. project called the Cancer Genome Atlas announced its first major achievement in September -- the mapping of genomes for breast and colon cancer. Scientists say they were able to identify 100 mutations thought responsible for each of those malignancies.
In March, British scientists reported that they had pinpointed 100 mutated genes that help drive more than 210 different cancer types. "This set of genes is known to regulate key functions in virtually all cell processes of growth, differentiation," researcher Andrew Futreal, of the Wellcome Trust Sanger Institute in Cambridge, said at the time.

And, in April, a team at Duke University said it had found genes that encourage breast cancer's spread to the lungs, as well as mutations that hamper chemotherapy's therapeutic effects.
It all looks very promising. But Lichtenfeld said that every DNA discovery has its downside, too.

"The more that we learn, the more complex it is going to get," he said. Indeed, the mapping of the breast and colon cancer genomes revealed that not only were the two cancers radically different in their origins, but that each tumor differed greatly between patients.

It's quickly become a very tangled web, experts say, but that's an inevitable part of the science.
"There may be a period of greatly evolving complexity that we have to get through which will only be sorted out by doing larger numbers across more genes," Futreal said.

Complicating matters further is the emerging field of epigenetics -- the study of how genes change their activity as they respond to their environment.

Still, certain "commonalities" could simplify things. Futreal pointed out that even though hundreds of genes can go awry and cause a cancer, many of these mutations will target the same cellular pathway. So, treatments that repair those broken pathways could fix a host of tumor types, he reasoned.

Today, however, only a small minority of cancer patients are directly benefiting from gene-based diagnostics or treatments. Those include women who carry the BRCA 1 and BRCA 2 breast cancer mutations, patients with chronic myelogenous leukemia (CML) who can take Gleevec, and early stage lung cancer patients who may soon benefit from those new prognostic tests.

And even when Americans find out that they do carry a certain gene posing an added risk, finding a qualified genetics counselor to sort it all out can be tough. There are only a handful of these experts in Lichtenfeld's hometown, Atlanta, he said, and they're practically unheard of in smaller centers.

"Most physicians simply aren't familiar with all the implications of assessing a woman's risk for breast cancer, for example, [or] of understanding all the genetic issues," Lichtenfeld noted. "So, I think that our theory right now is better than our practice. Our practice clearly needs to get better."

Nevertheless, things are greatly improved from decades past, when a patient with a family history of cancer was simply told to watch and wait and hope.

In the case of the BRCA 1 and BRCA 2 genes -- thought to cause up to 10 percent of breast cancers -- women now have real options to cut their risk, Lichtenfeld said. Using high-tech tests to spot the genes, women can make tough but potentially lifesaving decisions to have a breast removed or to take anti-cancer drugs such as tamoxifen to cut their odds for cancer by up to 80 percent.

Other tests aimed at spotting the HER-2 cancer gene and its product protein can dictate whether a patient's breast tumor will react favorably to the drug Herceptin.

"Many of these decisions aren't any easier than they were in the past, but at least now, they are much better informed," Lichtenfeld said. "And, looking into the future, this is going to become so much more a part of our diagnosis -- our ability to diagnose before we even see cancer. Typing the kind of cancer a patient has, too. And it's all going to become a huge part of cancer treatment."

More information
Find out more about cancer genetics at the American Cancer Society.

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Friday, September 14, 2007

Stopping Tysabri May Worsen MS

(HealthDay News) -- People suffering from multiple sclerosis who stopped taking the controversial drug Tysabri experienced a resurgence of brain lesions associated with their disease, researchers report.

But experts countered that the study was a small one and needs further confirmation.
"It's a valid report, [but] the study only involved 21 people," noted Dr. Randall Light, clinical assistant professor of family and community medicine with the Texas A&M Health Science Center College of Medicine and a neurologist with the Texas Brain and Spine Institute. "It's a heads-up for other researchers to share information," said Light, who was not involved in the study.

"This is an observation that needs further investigation and confirmation," agreed another expert, Dr. John Richert, executive vice president of research and clinical programs at the National Multiple Sclerosis Society in New York City.

Patients currently taking the drug should not discontinue it without seeking advice, the experts stressed.

"People taking the drugs should talk to a neurologist before," Light continued. "For patients, it just means don't stop taking the drug without talking to your doctor."

The findings were published Sept. 12 in the online edition of Neurology.

Tysabri (natalizumab), a monoclonal antibody, has been placed under a cloud of controversy for some time. The drug works by attaching itself to white blood cells called lymphocytes and preventing them from entering the brain, where they do damage that causes the disabling symptoms of MS. Tysabri had also been used to treat Crohn's disease.

But the drug has a checkered past. It first received U.S. Food and Drug Administration approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy.

In June 2006, the FDA allowed the drug to return to the market, but with strict conditions. According to the new guidelines, Tysabri can only be administered by approved doctors, at infusion sites and pharmacies that register and comply with a patient-safety program designed by Biogen-IDEC, the maker of Tysabri, and approved by the FDA.

According to the U.S. National Institutes of Health, multiple sclerosis is an unpredictable disease of the central nervous system that can range from relatively benign to somewhat disabling, to devastating, as communication between the brain and other parts of the body is disrupted.

Many researchers believe MS to be an autoimmune disease, one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is nerve-insulating myelin tissue that is under assault.

This trial was initiated after a neuroradiologist noticed that some patients were developing new lesions (as evidenced on MRI) after their Tysabri was discontinued.

All participants in this trial had had MRIs of their brains taken before starting Tysabri. They then had another such scan taken an average of 15 months after receiving the last infusion of the drug.

Participants were divided into two groups -- one which had taken the drug for an average of three years and one which had taken Tysabri for an average of only two months.

MRI scans revealed that participants developed more than triple the number of brain lesions (damaged areas) in the 15-month period since stopping the drug than they had developed before starting it. Those who had taken the drug for the shorter interval showed the most disease activity.

"Virtually all of the high-rebound figure came from the group that had a mean duration of therapy of only two months. I think that's relatively reassuring for the drug," Richert said.
MS symptoms did not show any sign of relapse, the team added.

The findings are in conflict with a previous study which found that people who had come off Tysabri did not show any rebound, Richert added. But the studies were a little different.

"They varied enough that both might be right, but we just don't know that yet," Richert added.

"Nevertheless, this is something that needs further study. I don't think that at this point it changes the way physicians and people with MS should be using the drug. We continue to need to be vigilant in the use of Tysabri."

More information
The National Multiple Sclerosis Society can tell you more about multiple sclerosis.

Friday, August 31, 2007

Heartburn Drugs Might Slow Heart Failure

By Ed EdelsonHealthDay Reporter

(HealthDay News) -- Over-the-counter antihistamine drugs used to treat heartburn and acid reflux might be useful against chronic heart failure, a Japanese study suggests.

It's a small study, including only 50 patients. But the results point to possible benefits for many of the 23 million Americans with heart failure, a potentially fatal condition in which the heart cannot pump blood effectively, said a report in the Oct. 3 issue of the Journal of the American College of Cardiology.

"It's still very early, because we know very little about who might benefit from it or what drugs might be best," said Dr. W.H. Wilson Tang, an assistant professor of medicine at the Cleveland Clinic and co-author of an accompanying editorial in the journal. "It is an important thing to validate this data."

The initial work focused on the drug Pepcid, because a major study of medical databases by a group led by Dr. Masafumi Kitakaze of Japan's National Cardiovascular Center found that people with heart failure who were also taking the antihistamine appeared to have fewer heart failure symptoms.

The researchers were looking for such a relationship because previous research pointed to a role of histamine in heart failure. The same type of chemical reaction that allows stomach acid to cause heartburn and ulcers also seems to damage and weaken diseased hearts. Blocking this process with Pepcid might help to slow the progression of chronic heart failure, the researchers theorized.

The biological chemistry is complex, but the basic idea is that one kind of histamine can accelerate the damage done to heart cells, so that blocking the activity of histamine can protect those cells.

Half the patients in the Japanese trial were given Pepcid along with regular therapy. The other half got an alternative heartburn medicine called teprenone, whose protective effect does not involve histamine. Examinations by three cardiologists after 24 weeks found less-severe symptoms in those getting Pepcid.

"Now we need to conduct a large-scale trial to confirm the present findings," Kitakaze said in a statement. "The large-scale trial based on the results of our present research may not help current heart-failure patients because it takes time, but we hope it helps our children and grandchildren and others in the future."

The key point, Tang said, is that the Japanese researchers "found some objective benefit of using this histamine blocker versus another reflux drug that doesn't act on this mechanism."
Further studies are essential not only to determine whether all antihistamine drugs might have some value against heart failure but also to identify drugs that might work best for specific patients, he said.

"It is intriguing because this work indicates that an inflammatory cell mechanism may be pertinent in heart failure," Tang said.

But it's much too early for people with heart failure to take antihistamines because of the many uncertainties that exist, he said.

More information
To learn more about heart failure, visit the American Heart Association.
SOURCES: W.H. Wilson Tang, assistant professor, medicine, Cleveland Clinic; Oct. 3, 2006, Journal of the American College of Cardiology

Tuesday, August 28, 2007

Diet and exercise work (here's how)

The July 20, 2007 issue of Science published the results of research conducted at Children’s Hospital in Boston which provides one explanation for the benefits of improved eating habits and exercise on life span.

Working with mice, Akiko Tachi, PhD, Lynn Wartschow, and Morris White of Harvard demonstrate that reducing insulin receptor substrate-2 (Irs-2) signaling increases life span as well as brain levels of superoxide dismutase, a protective antioxidant enzyme.

Acting on the basis of previous research in roundworms and fruit files which found an increase in life span associated with a reduction in insulin signaling, the trio engineered mice to reduce the amount of Irs-2, a protein that carries the insulin signal inside the cell, by half. Because reducing insulin signaling can cause diabetes, the researchers tested their hypothesis that reducing insulin signaling just in the brain, but not the rest of the body, would result in an increase in life span.

They engineered two groups of animals to experience a reduction in Irs-2 in their brains alone, while one group of animals was engineered to have lower Irs-2 in all cells, and another group served as controls.

“To our surprise, all of the engineered mice lived longer,” Dr Taguchi remarked. Despite being overweight and having higher insulin levels, animals with diminished brain insulin signaling experienced an 18 percent increase in lifespan compared to the normal controls. The mice were also more active and retained greater levels of superoxide dismutase in old age.

“The idea that insulin reduces lifespan is difficult to reconcile with decades of clinical practice and scientific investigation to treat diabetes,” Dr White noted. “The engineered mice live longer because the diseases that kill them – cancer, cardiovascular disease and others – are being postponed by reducing insulin-like signaling in the brain regardless of how much insulin there is in the rest of the body. The easiest way to keep insulin levels low in the brain is old-fashioned diet and exercise.”

“Our findings put a mechanism behind what your mother told when you were growing up—eat a good diet and exercise, and it will keep you healthy,” White observed. “Diet, exercise and lower weight keep your peripheral tissues sensitive to insulin. That reduces the amount and duration of insulin secretion needed to keep your glucose under control when you eat. Therefore, the brain is exposed to less insulin. Since insulin turns on Irs2 in the brain, that means lower Irs2 activity, which we’ve linked to longer lifespan in the mouse.”

“We are beginning to appreciate that obesity, insulin resistance, and high blood insulin levels are connected to Alzheimer’s disease, Huntington’s disease, and dementias in general,” he added. “It might be that, in people who are genetically predisposed to these diseases, too much insulin overactivates Irs2 in the brain and accelerates disease progression. Thus, insulin resistance and higher insulin levels might be the environmental influences that promote these diseases.”

Thursday, August 02, 2007

Test Brings Early Pancreatic Cancer to Light

(HealthDay News) -- A light-based test that doesn't focus on the pancreas itself may be the first safe means of accurately spotting early pancreatic cancer in people at high risk for the lethal illness, researchers say.

The screening requires a routine endoscopic biopsy of the duodenum, the upper part of the small intestine. When an early-stage pancreatic cancer is present, cells in the duodenum give off different light-scattering effects than if the disease is not there, U.S. researchers explain in the Aug. 1 issue of Clinical Cancer Research.

In the small pilot study of 51 patients, the optical screen was 100 percent effective in spotting patients with surgically removable pancreatic tumors.

"This is potentially a way of prescreening [high-risk] patients," said lead researcher Vadim Backman, a professor of biomedical engineering at Northwestern University's McCormick School of Engineering and Applied Sciences, in Evanston, Ill.

He explained that patients with a family history of pancreatic cancer now "live their whole life thinking, 'What is going to happen to me?'"

He added that the new test raises "a possibility of taking these patients and screening them on an annual basis without risk."

The test, which has already proven useful in detecting early-stage colon cancer using rectal tissue, does need to be validated in a larger, prospective trial, experts said.

However, if that works out, "it would be a very important tool for our patient community, as well as the doctors that treat them," said Julie Fleshman, president and CEO of the nation's largest nonprofit pancreatic cancer advocacy group, the Pancreatic Cancer Action Network (PanCAN).

"We look at this with hopeful optimism," she added. "The study was done in a small number of patients, however, so more research needs to be done."

Any advance would be welcome against pancreatic cancer, the fourth leading cancer killer in the United States. According to the American Cancer Society, more than 33,000 Americans die annually from the disease, which is especially lethal because it typically shows no symptoms until it has already spread to other organs.

Opera superstar Luciano Pavarotti is perhaps the most high-profile patient currently battling the illness, which has few effective treatments.

"The survival rate is extremely low, lower than any other type of cancer -- below 5 percent over five years, and a third of patients die within one year of diagnosis," Backman said.
The scanning technologies that can detect other tumors can't pick up early-stage pancreatic cancer, he noted, and invasive tests that biopsy or probe the pancreas come with a more than 20 percent risk of serious complications. "It's an extremely difficult organ to work with," the researcher said.

However, the Northwestern team had already tested its light-based technology in colon cancer. The researchers found that it could pick up traces of early malignancy using biopsies taken from a separate but adjacent site, the rectum.

"So, we asked the question, 'Can we find out if a patient has pancreatic cancer or not without actually going inside the pancreas?' " Backman explained.

They honed in on the duodenum, a portion of the small intestine that lies very near the pancreas, but is much more accessible to biopsy. In a study of the 51 patients -- some of whom had various stages of pancreatic cancer -- the scientists used standard upper endoscopy to retrieve a tiny biopsy of duodenal tissue.

Then they subjected cells from these tissues to two light-scattering tests designed to detect aberrations that signal a nearby pancreatic malignancy.

The results were impressive, with the researchers achieving 100 percent accuracy in spotting both early- and later-stage pancreatic tumors.

A few false-positives were also reported, the team noted. It's not clear whether these results were simply wrong, or if they suggested that those patients were at high risk of developing pancreatic cancer in the future and needed to be monitored closely.

Both Backman and Fleshman stressed that such a test would probably only be used as routine screening on patients with a family history of pancreatic disease. "We do know that about 10 percent of cases are genetic," Fleshman pointed out.

A pancreatic cancer test aimed at the wider population -- similar to the way women get regular mammograms or men go for PSA prostate cancer blood tests -- is still a long way off, she said.
"I hope someday that we do have something that is part of a regular physical for a disease like this," Fleshman said. "But I don't think that that is on the near horizon."

In the meantime, Backman's team is already engaged in a larger trial involving more than 200 patients. That trial will examine how good the optical tests are at differentiating between pancreatic cancer and other, benign conditions that can affect the organ, such as pancreatitis or cysts.

"We will also compare patients with a family history against those who don't have a family history," he said.

Fleshman said her group is excited by the test's potential, but much more work needs to be done.

"This continues to illustrate the need for more research dollars into this disease," she said. "Because, even if we found an early detection method, we still need much better treatment options for patents."

More information
There's more on the fight against pancreatic cancer at PanCAN.

Monday, June 18, 2007

Vitamin D Cuts Cancer Risk: Study

(HealthDay News) -- Boosting your vitamin D intake can dramatically reduce your risk of breast and other cancers, a new study found.

The research adds to growing evidence that vitamin D can help protect against many forms of cancer as well as other diseases, Creighton University researchers said.

But an American Cancer Society spokeswoman urged caution in interpreting the findings, saying it was premature to recommend taking vitamins to reduce cancer risk.

Joan Lappe, a Creighton University professor of medicine and nursing and lead author of the study, said, "What we can say from our study is that 1,100 international units (IUs) a day of vitamin D definitely decreased the incidence of cancer."

That amount of the vitamin is nearly triple the recommended intake for the age group studied -- women who were 55 and older when the four-year study started.

Lappe's team followed 1,179 study participants who were all postmenopausal and lived in rural Nebraska. The women were free of known cancers for the 10 years before entering the study. They were assigned to one of three groups and followed for four years.

One group took 1,400 to 1,500 milligrams of supplementary calcium a day, another group took that same amount of calcium plus 1,100 IUs of vitamin D daily, while the third group took placebo pills every day.

After four years, those in the combination vitamin D and calcium group had a 60 percent lower risk of developing cancer, compared to the placebo group. The calcium-only group had a 47 percent reduced risk.

Then the researchers eliminated data from the first year of the study, figuring some women may have entered the study with cancer that had not yet been diagnosed. The results were more dramatic, Lappe said.

When the researchers looked at results from just the last three years of the trial, they found the combination calcium-and-vitamin D group had a 77 percent reduced risk of cancers, compared to the placebo group. The risk for the calcium-only group was essentially unchanged.

In all, a total of 50 women got non-skin cancers during the study, with breast cancer the most common. The other cancers included lung and colon tumors.

The findings are published in the June edition of the American Journal of Clinical Nutrition.
In May, Harvard Medical School researchers reported in the Archives of Internal Medicine that high intakes of vitamin D and calcium cut the risk of breast cancer by nearly one-third in premenopausal women, but not women past menopause.

Dr. Michael Holick, professor of medicine, physiology and biophysics at the Boston University School of Medicine and a long-time vitamin D researcher, said the Lappe study adds to growing evidence of the health and disease-fighting effects of vitamin D.

"It's very clear the data are significant," he said of the Lappe study.

Vitamin D is thought to act through the immune system to help prevent the formation of abnormal cells, Lappe said.

To date, both Lappe and Holick said, high intake of vitamin D has been found to reduce the risk of many forms of cancer as well as type 1 diabetes, multiple sclerosis, rheumatoid arthritis and high blood pressure.

Both researchers think the current recommendations for daily vitamin D intake should be boosted. The U.S. Institute of Medicine, which makes recommendations on vitamin and mineral requirements, considers 200 IUs of vitamin D adequate for children and adults up to age 50;

400 IUs adequate for adults 51 to 70, and 600 for those 71 and older. The levels aren't Recommended Dietary Allowances, or RDAs, because the institute doesn't think there's enough evidence to establish an RDA for vitamin D.

"I think it's safe to say the current recommendations are much too low," Lappe said, adding that postmenopausal women should "probably be taking 1,100 IUs a day."

She recommends vitamin D3 supplements, the type used in the study, over D2, because D3 is more active, she said.

But Marji McCullough, strategic director of nutritional epidemiology for the American Cancer Society, who is familiar with the new study and other similar research, said in a prepared statement that the society doesn't currently recommend taking vitamin or mineral supplements to reduce cancer risk. But it has joined other health organization to weigh the evidence of vitamin D, and a joint panel recommends supplementation and small amounts of ultraviolet exposure "as the best way to achieve proper vitamin D status."

While she called the new study "intriguing,'' she said the number of participants was small and the research needs to be replicated before firmer conclusions can be drawn.

Discuss vitamin D intake with your doctor. And be aware that the Institute of Medicine has declared that 2,000 IUs is the upper tolerable, or safe, level for most people. For babies up to 1 year old, the limit is 1,000 IUs, McCullough said.

Vitamin D, which is important for strong bones, is found in salmon and other fish, and fortified milk and fortified cereals, among other foods.

Supplements aren't the only potential way to fight disease. In the same issue of the journal, another report found that a high intake of whole grain foods reduced the risk of atherosclerosis, or hardening of the blood vessels, which can lead to heart disease.

U.S. researchers tracked 1,178 men and women, from 40 to 69 years old at the start of the study, and found that eating more whole grains was associated with a lower risk of atherosclerosis.

More information
To learn more about vitamin D and cancer, visit the American Cancer Society.

Tuesday, June 12, 2007

Alzheimer's Drug Trials Offer Promising Results

(HealthDay News) -- Decades of work in the laboratory may finally be paying off for Alzheimer's disease patients, as clinical trials show a variety of drugs making headway against the illness.

Two drugs, Dimebon and the diabetes medication Avandia, may help curb Alzheimer's in different ways. And close to five years of follow-up data suggest that an "Alzheimer's vaccine" might someday harness the power of the immune system to protect against dementia.

All of these agents work to alter the progression of the underlying disease, not just mask or limit its symptoms, as current Alzheimer's drugs do.

With so many varied means of attacking Alzheimer's disease on the horizon, "the clinician will have more of an arsenal to treat the patient from different approaches," said Dr. Paul Sanberg, director of the Center of Excellence for Aging and Brain Repair at the University of South Florida in Tampa.

"And what we don't even know yet is whether there are synergistic effects we could get by combining these approaches," he added.

Sanberg was not involved in the studies, the results of which were presented Monday at a special press briefing at the Alzheimer's Association's International Conference on Prevention of Dementia, in Washington, D.C.

Alzheimer's disease now affects more than 5 million Americans, according to the Alzheimer's Association. Scientists project that unless new ways are found to prevent or treat the disease, that total could climb to 16 million by mid-century. The exact causes of the illness are not known, but disease progression is highly associated with the build-up of clumped beta amyloid proteins in the brain.

One compound showing promise in a one-year trial is Dimebon, which targets Alzheimer's on a variety of fronts. According to Dr. William Thies, vice president of medical and scientific affairs at the Alzheimer's Association, the drug has symptom-limiting properties similar to anticholinesterase medications (such as Aricept) and another class of Alzheimer's drugs, called glutamate antagonists.

Dimebon may also protect vulnerable brain cells from amyloid build-up by boosting the energy output of cellular "power plants" called mitochondria.

So, besides affecting the symptoms of Alzheimer's disease, Dimebon "also has disease-modifying effects, bringing neurons long-term protection against loss of function," Thies explained.

In the trial, 120 patients in Russia with mild to moderate Alzheimer's were randomly chosen to receive either oral Dimebon or a placebo three times daily for 12 months. A team of researchers led by Dr. Rachelle Doody of Baylor College of Medicine in Houston then followed changes in the four most frequently studied aspects of the disease -- cognition, clinical function, activities of daily living and behavioral issues.

The researchers said patients on Dimebon achieved statistically significant improvements in all of these endpoints, and those improvements remained stable or even increased over the 12 months of the study. The dropout rate was similar between those on a placebo or Dimebon (about one-third of patients), and side effects were relatively low and included dry mouth (18 percent) and depression (14.6 percent).

"The natural history of untreated Alzheimer's disease includes decline in thinking abilities, social behavior and function," Doody said in a prepared statement released by the makers of Dimebon, Medivation. "By contrast, after a full year of therapy, Dimebon-treated patients did not decline in any of these areas." Medivation plans a six-month phase 3 clinical trial of the drug beginning in 2008.

A second study focused on a "Holy Grail" of neurological research: an Alzheimer's vaccine. One immune antibody-based shot called AN 1792 did show promise in small clinical trials involving 129 Alzheimer's patients, which were conducted nearly five years ago. However, hopes for the vaccine were dashed after 6 percent of the participants developed treatment-linked brain inflammation.

Although none of the affected patients died from the encephalopathy, the side effects "really did sidetrack AN 1792 as a product," Thies said, bringing a halt to further trials.

But doctors have continued to follow the mental-health histories of the trial's 25 "antibody responders" -- patients whose immune systems reacted favorably to the injection.

Antibodies are still active in blood samples taken from those patients, the researchers reported on Monday. Furthermore, these "responders showed significantly slower decline on the Disability Assessment for Dementia than placebo patients," according to the international team of researchers, led by Dr. Leon Thal of the University of California, San Diego.

"We've also seen a steady stream of autopsy data from people who were in the study demonstrating less amyloid than what one could expect," Thies noted.

So, even though AN 1792 may never make it to patients, these positive long-term outcomes mean immunotherapy research is very much alive.

"In fact, there are next-generation immunotherapies that are going forward as we speak," Thies said.

Then there's Avandia, a drug used by millions to combat diabetes, which has also appeared useful in slowing Alzheimer's in prior studies. In a new study, drugs maker GlaxoSmithKline presented safety data from a 16-month clinical trial involving 337 patients with mild to moderate Alzheimer's. The patients received either Avandia (rosiglitazone XR) or a placebo daily.

The trial, which was only designed to assess the safety and tolerability of the drug in Alzheimer's patients, found that 82 percent of participants did complete the 16 months of treatment. While about half of the patients experienced some side effects (for example, swelling), only a very few (less than 2 percent) experienced any cardiovascular abnormalities tied to the drug.

That's important, because an article last month in the New England Journal of Medicine tied long-term Avandia use by diabetics to increased heart risk. On June 6, the FDA asked that the medication carry a "black box" warning label, noting a potentially heightened risk of congestive heart failure in some patients using Avandia.

However, when it comes to treating Alzheimer's, Thies believes that "the relatively modest risk would be reasonably well-accepted by the community because of the [drug's] benefits against Alzheimer's."

Experts aren't quite sure how Avandia might ease Alzheimer's. The drug has anti-inflammatory properties, which might help, and it also helps boost the brain cell's energy supply, giving it more resilience against amyloid build-up and other Alzheimer's-related brain insults, Thies said.
A fourth study -- on an amyloid-clearing agent-- was presented at the conference on Monday with no clear message for patients yet.

Researchers at drug company Neurochem Inc. said that the results of their phase III trial of Alzhemed (tramiprosate) are in, but that the findings are too varied across the trial sites and too complex to determine the drug's efficacy at this point.

The Alzhemed study results were highly anticipated because this was the first phase III trial of any amyloid-clearing agent.

"Basically what Alzhemed does is interfere with that clumping of amyloid, so that normal clearance mechanisms can remove the amyloid before it forms plaques," Thies explained.

More information
Find out more about Alzheimer's disease at the Alzheimer's Association

Weight Loss Ebook - Secrets Revealed - Revised Edition

Weight Loss Ebook - Secrets Revealed - Revised Edition

$19.95
[ learn more ]

Add to Cart

This is not only a weight loss program, it is also a plan for "TOTAL HEALTH". If you want a quick fix (taking metabolism boosters, etc.), only to gain more weight when you stop, do not even consider this program. Our program is designed to change the way you think and live your life. Change is only a decision away. You can do this! If you are motivated, and truly care about taking care of your body, and you are willing to make changes in your life, then this program is for you! - E-Book Version.(WL)